Recro to Report Fourth Quarter and Year-End 2020 Financial Results Earlier Than Previously Announced
Recro Pharma (REPH) has rescheduled its Q4 2020 earnings release to February 26, 2021, before the market opens.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Recro Pharma (REPH) has rescheduled its Q4 2020 earnings release to February 26, 2021, before the market opens. The company will hold a conference call at 8:00 a.m. ET on the same day to discuss the financial results and operational highlights. Recro operates as a contract development and manufacturing organization (CDMO) specializing in oral solid dosage forms and offers services from development to commercial manufacturing. The company operates facilities totaling 120,000 sq. ft. in Gainesville, Georgia.
Details
News Market Reaction – REPH
The recorded move for REPH in the trading session of this news was +3.70%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call and Webcast Moved Up to 8:00 a.m. Eastern on Friday, February 26
MALVERN, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced that it moved up the time of its previously announced quarterly earnings release and conference call. The company will now report its financial results for the fourth quarter and year-end 2020 prior to the opening of the market on Friday, February 26, 2021, as opposed to post-market on that day. Recro’s management team will then host a conference call and audio webcast at 8:00 a.m. ET on Friday, February 26, 2021 to discuss the financial results and recent operational highlights.
To access the live conference call please dial (844) 243-4691 from the U.S. or (225) 283-0379 from outside the U.S. at least ten minutes prior to the start time and reference conference ID 3352999. Those interested in listening to the conference call live via webcast may do so by visiting the “Events” page in the Investor section of the Company’s website, www.recrocdmo.com. In addition, an archived webcast will be available on the Company’s website approximately two hours after the event and will be available for 30 days.
About Recro
Recro (NASD: REPH) is a contract development and manufacturing organization (CDMO) with capabilities from early feasibility to commercial manufacturing. With an expertise in solving complex manufacturing problems, Recro is a leading CDMO providing oral solid dosage form development, end-to-end regulatory support, clinical and commercial manufacturing, and packaging and logistics services to the global pharmaceutical market.
In addition to our experience in handling DEA controlled substances and developing and manufacturing modified release oral solid dosage forms, Recro has the expertise to deliver on our clients’ pharmaceutical development and manufacturing projects, regardless of complexity level. We do all of this in our best-in-class facilities, which total 120,000 square feet, in Gainesville, Georgia.
For more information about Recro’s CDMO solutions, visit recrocdmo.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.